Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 18/20 | 0.70 |
| ▸ | F2 | P00734 | 4/20 | 0.70 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.70 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.51 |
| ▸ | CDK2 | P24941 | 1/20 | 0.51 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.51 |
| ▸ | PDE4A | P27815 | 1/20 | 0.50 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.50 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.50 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18028085 | 0.97 | F10 (0.66) | F10F2SLC29A1CCNA2CDK2 | |
| SCHEMBL18028114 | 0.91 | F10 (0.59) | F10F2SLC29A1CCNA2CDK2 | |
| SCHEMBL19587062 | 0.91 | F10 (0.59) | F10F2SLC29A1CCNA2CDK2 | |
| SCHEMBL1996263 | 0.90 | F10 (0.69) | F10F2SLC29A1CCNA2CDK2 | |
| SCHEMBL15883212 | 0.89 | F10 (0.80) | F10F2SLC29A1 | |
| SCHEMBL16730471 | 0.89 | F10 (0.68) | F10F2SLC29A1CCNA2CDK2 | |
| SCHEMBL18028118 | 0.88 | F10 (0.63) | F10F2SLC29A1CCNA2CDK2 | |
| SCHEMBL17766180 | 0.88 | F10 (0.78) | F10F2SLC29A1 | |
| SCHEMBL16730454 | 0.88 | F10 (0.67) | F10F2SLC29A1 | |
| SCHEMBL18028070 | 0.87 | F10 (0.68) | F10F2SLC29A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9815833-B2 | Pyridine derivative and medical use thereof | CHENGDU EASTON BIOPHARMACEUTICALS CO., LTD. (CN) | 2017-11-14 | — | — | US | disclosed |
| US-20170291896-A1 | PYRAZOLO[3,4-C]PYRIDINE DERIVATIVES | CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) | 2017-10-12 | — | — | US | disclosed |
| US-20160244440-A1 | PYRIDINE DERIVATIVE AND MEDICAL USE THEREOF | Zhejiang Yatai Pharmaceutical Co., Ltd. (CN) | 2016-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170291896-A1 | PYRAZOLO[3,4-C]PYRIDINE DERIVATIVES | F11, TFPI, F2 | F10 10/4885F2 3/4885SLC29A1 2786/4885 |
| US-20160244440-A1 | PYRIDINE DERIVATIVE AND MEDICAL USE THEREOF | PEPD, F2, XDH | F10 35/4885F2 2/4885SLC29A1 3438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.